Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

Novartis announces the appointment of the

Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the

Sandoz Biologics License Application for proposed

Submission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of

Patients with hidradenitis suppurativa experienced

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment

Sandoz receives positive CHMP opinion for citrate-free high

Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference